{"publication_id":"faf58aa1-0279-46d8-a52f-a9e3f585c07c","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review","doi":"10.3390/ijms25084346","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials","doi":"10.1111/obr.13792","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials","doi":"10.3390/ph14100991","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","doi":"10.1038/s41591-024-02996-7","risk_of_bias":"not appraised in public sidecar","directness":"primary"}]}